JP2021506243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506243A5 JP2021506243A5 JP2020531949A JP2020531949A JP2021506243A5 JP 2021506243 A5 JP2021506243 A5 JP 2021506243A5 JP 2020531949 A JP2020531949 A JP 2020531949A JP 2020531949 A JP2020531949 A JP 2020531949A JP 2021506243 A5 JP2021506243 A5 JP 2021506243A5
- Authority
- JP
- Japan
- Prior art keywords
- cell line
- immortalized
- cell
- seq
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091008874 T cell receptors Proteins 0.000 claims 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims 7
- 102000002090 Fibronectin type III Human genes 0.000 claims 5
- 108050009401 Fibronectin type III Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 101000945490 Homo sapiens Killer cell immunoglobulin-like receptor 3DL2 Proteins 0.000 claims 4
- 102100034840 Killer cell immunoglobulin-like receptor 3DL2 Human genes 0.000 claims 4
- 230000031146 intracellular signal transduction Effects 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 108010042407 Endonucleases Proteins 0.000 claims 2
- 102000004533 Endonucleases Human genes 0.000 claims 2
- 108700005077 Viral Genes Proteins 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598032P | 2017-12-13 | 2017-12-13 | |
| US62/598,032 | 2017-12-13 | ||
| PCT/US2018/064971 WO2019118475A1 (en) | 2017-12-13 | 2018-12-11 | Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506243A JP2021506243A (ja) | 2021-02-22 |
| JP2021506243A5 true JP2021506243A5 (enExample) | 2022-01-11 |
Family
ID=66734891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531949A Pending JP2021506243A (ja) | 2017-12-13 | 2018-12-11 | Ｔ細胞受容体及びβ２ミクログロブリン発現を排除するように遺伝子改変された不死化ＣＡＲ−Ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190175651A1 (enExample) |
| EP (1) | EP3724321A4 (enExample) |
| JP (1) | JP2021506243A (enExample) |
| KR (1) | KR20200088383A (enExample) |
| CN (1) | CN111479917A (enExample) |
| AU (1) | AU2018386010A1 (enExample) |
| CA (1) | CA3082204A1 (enExample) |
| SG (1) | SG11202003864XA (enExample) |
| WO (1) | WO2019118475A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| RU2759952C2 (ru) | 2016-12-14 | 2021-11-19 | Янссен Байотек, Инк. | Cd8a-связывающие домены типа iii фибронектина |
| EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| CN111093696B (zh) * | 2017-07-17 | 2023-10-27 | 詹森生物科技公司 | 抗iii型纤连蛋白结构域的抗原结合区及其使用方法 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CA3141327A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Operations, Inc. | Madcam targeted immunotolerance |
| CN118515779A (zh) | 2019-07-26 | 2024-08-20 | 詹森生物科技公司 | 抗hk2嵌合抗原受体（car） |
| US12344656B2 (en) | 2019-09-06 | 2025-07-01 | Crispr Therapeutics Ag | Genetically engineered T cells having improved persistence in culture |
| US12491255B2 (en) | 2019-10-14 | 2025-12-09 | Aro Biotherapeutics Company | EPCAM binding fibronectin type III domains |
| US11628222B2 (en) | 2019-10-14 | 2023-04-18 | Aro Biotherapeutics Company | CD71 binding fibronectin type III domains |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| CA3214552A1 (en) * | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| CA3215367A1 (en) | 2021-04-14 | 2022-10-20 | Swapnil Kulkarni | Fn3 domain-sirna conjugates and uses thereof |
| CN117693519A (zh) * | 2021-05-25 | 2024-03-12 | 瓦克斯细胞生物 | 基于单体拟抗体的嵌合抗原受体和包含其的免疫细胞 |
| IL311307A (en) * | 2021-09-10 | 2024-05-01 | Kite Pharma Inc | Alternative generation of human allogeneic T cells |
| CN116023496A (zh) * | 2021-10-27 | 2023-04-28 | 深圳市菲鹏生物治疗股份有限公司 | 一种制备通用型car-t细胞的方法及其应用 |
| US12006353B2 (en) | 2022-07-25 | 2024-06-11 | Long Chen | Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof |
| EP4665845A1 (en) * | 2023-02-17 | 2025-12-24 | The Regents of University of California | Pluripotent stem cell-engineered immune cells for off-the-shelf cell therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9200273B2 (en) * | 2011-09-27 | 2015-12-01 | Janssen Biotech, Inc. | Fibronectin type III repeat based protein scaffolds with alternative binding surfaces |
| EP3693384B1 (en) * | 2014-03-11 | 2024-01-24 | Cellectis | Method for generating t-cells compatible for allogenic transplantation |
| JP7054622B2 (ja) * | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| CN107206024B (zh) * | 2014-10-31 | 2021-12-03 | 宾夕法尼亚大学董事会 | 改变cart细胞中的基因表达及其用途 |
| EA201792441A2 (ru) * | 2015-05-06 | 2018-06-29 | Янссен Байотек, Инк. | Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном |
| WO2017106528A2 (en) * | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the t cell receptor |
| WO2017106537A2 (en) * | 2015-12-18 | 2017-06-22 | Sangamo Biosciences, Inc. | Targeted disruption of the mhc cell receptor |
| WO2017112859A1 (en) * | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| WO2018052828A1 (en) * | 2016-09-14 | 2018-03-22 | Janssen Biotech, Inc. | Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof |
-
2018
- 2018-12-11 AU AU2018386010A patent/AU2018386010A1/en not_active Abandoned
- 2018-12-11 JP JP2020531949A patent/JP2021506243A/ja active Pending
- 2018-12-11 SG SG11202003864XA patent/SG11202003864XA/en unknown
- 2018-12-11 EP EP18888643.6A patent/EP3724321A4/en not_active Withdrawn
- 2018-12-11 CN CN201880080452.1A patent/CN111479917A/zh active Pending
- 2018-12-11 KR KR1020207016631A patent/KR20200088383A/ko not_active Ceased
- 2018-12-11 US US16/215,716 patent/US20190175651A1/en not_active Abandoned
- 2018-12-11 WO PCT/US2018/064971 patent/WO2019118475A1/en not_active Ceased
- 2018-12-11 CA CA3082204A patent/CA3082204A1/en active Pending
- 2018-12-11 US US16/770,809 patent/US20200332255A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021506243A5 (enExample) | ||
| JP7306731B2 (ja) | ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾 | |
| JP2023080187A (ja) | 増強されたキメラ抗原受容体およびその使用 | |
| JP7783746B2 (ja) | 操作されたｉＰＳＣおよび免疫エフェクター細胞におけるＣＤ３の再構成 | |
| CN106103475B (zh) | 产生同种异体移植相容的t细胞的方法 | |
| JP2021505131A (ja) | 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 | |
| JP2021506236A (ja) | 強化された免疫エフェクター細胞およびその使用 | |
| JP2017529851A5 (enExample) | ||
| JP2018529380A5 (enExample) | ||
| JP2020509050A5 (enExample) | ||
| CN114901693A (zh) | 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途 | |
| JP2017537622A5 (enExample) | ||
| NZ791176A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| JP2018514204A5 (enExample) | ||
| WO2018205926A1 (zh) | 经修饰的t细胞、其制备方法及用途 | |
| JP2017513478A5 (enExample) | ||
| JP2024537991A (ja) | 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞 | |
| WO2023158836A1 (en) | Engineered cd47 proteins and uses thereof | |
| CN114729315A (zh) | 用于提供具有增强功能的免疫细胞的方法 | |
| IL302476A (en) | Engineered ipsc and immune effector cells for heterogenous tumor control | |
| CA3196555A1 (en) | Multiplexed engineered ipsc and immune effector cells targeting solid tumors | |
| IL301983A (en) | Transgenic induced pluripotent stem cells and effector carrier cells of the immune system | |
| CN113631184A (zh) | 通过抑制ebag9增强溶细胞性t细胞活性 | |
| WO2024097315A2 (en) | Cell therapy products and methods for producing same | |
| US20240307540A1 (en) | Protected effector cells and use thereof for allogeneic adoptive cell therapies |